Narval
Zapopan · Founded 2024
About Narval
Narval develops next-generation of antibody-like drugs using macrocyclic synthetic proteins that mimicthe activity of antibodies and can be delivered through mucosal tissues for localized treatment and non-systemic delivery. Our Antibody Mimetic Proteins, or AMP for short, are developed by fusing CDR3 regions of a single domain shark antibodies to a conoprotein scaffold from a sea snail, and we optimize their capabilities using AI and ML algorithms. Narval’s AMPs offer a breakthrough solution for fast, accessible, and deployable therapeutics in areas like pandemics, emergency outbreaks, biodefense, animal health, and agricultural biosecurity.
Company Facts
- Founded: 2024
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $167.0K
- Funding stage: Seed
- Last round: Pre-Seed (Mar 2024)
- Website: https://narvalbio.com/
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/narval-9327 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.